亚辉龙收盘上涨1.44%，滚动市盈率36.02倍，总市值88.47亿元

Company Overview - Shenzhen Aihuilong Biotechnology Co., Ltd. specializes in the research, production, and sales of in vitro diagnostic instruments and related reagents, primarily using chemiluminescence immunoassay technology [2] - The company has developed a fully automated immunoassay system, breaking the technological monopoly of foreign giants in the field of acridine ester chemiluminescence [2] - Aihuilong's quality management system meets international standards, with major products certified by ISO9001, ISO13485, and EU CE [2] Financial Performance - For Q1 2025, the company reported revenue of 418 million yuan, a year-on-year decrease of 3.13%, and a net profit of 10.148 million yuan, down 84.63% year-on-year [2] - The sales gross margin stood at 59.49% [2] Market Position - As of August 15, Aihuilong's stock closed at 15.51 yuan, with a rolling PE ratio of 36.02, and a total market capitalization of 8.847 billion yuan [1] - The average PE ratio in the medical device industry is 56.58, with a median of 39.97, placing Aihuilong at the 70th position in the industry ranking [1][3] - The company has one institutional holder, with a total holding of 0.14 thousand shares, valued at 0.00 billion yuan [1]